NCT01012973 - Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) | Biotech Hunter

Enrollment

177

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

February 29, 2012

Conditions

Retinal Vein Occlusion

Interventions

BIOLOGICAL

Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.

OTHER

Sham treatment

Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.

Trial Locations (73)

1002

Riga

1050

Riga

1089

Budapest

1090

Vienna

1106

Budapest

1133

Budapest

2000

Sydney

2067

Chatswood

2145

Westmead

2150

Parramatta

3002

East Melbourne

4021

Linz

4032

Debrecen

6009

Nedlands

6020

Innsbruck

8200

Veszprém

10122

Torino

13008

Marseille

13353

Berlin

20122

Milan

20132

Milan

20157

Milan

20251

Hamburg

21033

Dijon

23538

Lübeck

24105

Kiel

33000

Bordeaux

35037

Marburg

35128

Padua

37075

Göttingen

44093

Nantes

45122

Essen

48145

Münster

50134

Florence

50924

Cologne

52074

Aachen

53105

Bonn

55131

Mainz

60126

Ancona

60596

Frankfurt am Main

64297

Darmstadt

66421

Homburg

67063

Ludwigshafen am Rhein

69120

Heidelberg

70124

Bari

72076

Tübingen

75015

Paris

75557

Paris

79106

Freiburg im Breisgau

81675

München

93053

Regensburg

95123

Catania

119074

Singapore

168751

Singapore

09116

Chemnitz

01307

Dresden

06067

Dresden

04103

Leipzig

H-8900

Zalaegerszeg

00133

Roma

00198

Roma

466-8560

Nagoya

467-8602

Nagoya

279-0021

Urayasu

606-8507

Kyoto

565-0871

Suita

101-8309

Chiyoda-ku

463-707

Seongnam-si

405-760

Incheon

110 744

Seoul

137-701

Seoul

138-736

Seoul

Unknown

Seoul